Apo E structure determines VLDL clearance and atherosclerosis risk in mice

被引:259
作者
Knouff, C
Hinsdale, ME
Mezdour, H
Altenburg, MK
Watanabe, M
Quarfordt, SH
Sullivan, PM
Maeda, N [1 ]
机构
[1] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA
[2] Vet Affairs Med Ctr, Dept Med, Durham, NC 27705 USA
[3] Duke Univ, Med Ctr, Durham, NC 27705 USA
关键词
D O I
10.1172/JCI6172
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We have generated mice expressing the human apo E4 isoform in place of the endogenous murine apo E protein and have compared them with mice expressing the human apo E3 isoform, Plasma lipid and apolipoprotein levels in the mice expressing only the apo E4 isoform (4/4) did not differ significantly from those in mice with the apo E3 isoform (3/3) on chow and were equally elevated in response to increased lipid and cholesterol in their diet. However, on all diets tested, the 4/4 mice had approximately twice the amount of cholesterol, apo E, and apo B-48 in their VLDL as did 3/3 mice. The 4/4 VLDL competed with human LDL for binding to the human LDL receptor slightly better than 3/3 VLDL, but the VLDL clearance rate in 4/4 mice was half that in 3/3 mice. On an atherogenic diet, there was a trend toward greater atherosclerotic plaque size in 4/4 mice compared with 3/3 mice. These data, together with our earlier observations in wild-type and human APOE*2-replacement mice, demonstrate a direct and highly significant correlation between VLDL clearance rate and mean atherosclerotic plaque size. Therefore, differences solely in apo E protein structure are sufficient to cause alterations in VLDL residence time and atherosclerosis risk in mice.
引用
收藏
页码:1579 / 1586
页数:8
相关论文
共 39 条
[1]   Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele [J].
Bergeron, N ;
Havel, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) :65-72
[2]  
BOERWINKLE E, 1988, AM J HUM GENET, V42, P104
[3]  
Bohnet K, 1996, J LIPID RES, V37, P1316
[4]   TYPE-III HYPERLIPOPROTEINEMIA - DIAGNOSIS, MOLECULAR DEFECTS, PATHOLOGY, AND TREATMENT [J].
BREWER, HB ;
ZECH, LA ;
GREGG, RE ;
SCHWARTZ, D ;
SCHAEFER, EJ .
ANNALS OF INTERNAL MEDICINE, 1983, 98 (05) :623-640
[5]   Constructing collaborative learning activities for distance CAL systems [J].
Chang, CK ;
Chen, GD .
JOURNAL OF COMPUTER ASSISTED LEARNING, 1997, 13 (01) :2-15
[6]   Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages [J].
Cullen, P ;
Cignarella, A ;
Brennhausen, B ;
Mohr, S ;
Assmann, G ;
von Eckardstein, A .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1670-1677
[7]   APOLIPOPROTEIN-E POLYMORPHISM AND ATHEROSCLEROSIS [J].
DAVIGNON, J ;
GREGG, RE ;
SING, CF .
ARTERIOSCLEROSIS, 1988, 8 (01) :1-21
[8]  
DEMANT, 1991, J CLIN INVEST, V88, P490
[9]  
FORTE TM, 1986, METHOD ENZYMOL, V128, P442
[10]  
GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153